Acotec Scientific Holdings Limited (6669) AI Stock Analysis

• Market Cap: HK$4.01B
• Dividend Yield: N/A
• Average Volume (3M): 416.48K
• Price to Earnings (P/E): 72.2
• Beta (1Y): 0.94
• Revenue Growth: 10.44%
• EPS Growth: 238.85%
• Country: HK
• Employees: 650
• Sector: Technology
• Sector Strength: 90
• Industry: Medical - Devices
• EPS (TTM): 0.04
• Shares Outstanding: 313,389,160
• 10 Day Avg. Volume: 553,056
• 30 Day Avg. Volume: 416,481
• PEG Ratio: -0.38
• Price to Book (P/B): 3.56
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -39.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$7.51
• Price Target Upside: -37.27% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 72 Outperform
• Price Target: HK$15.00 ▲(25.21%Upside)

Acotec Scientific Holdings benefits from strong technical momentum and a healthy balance sheet, contributing positively to the stock score. However, the high P/E ratio and overbought technical indicators suggest caution. The lack of earnings call data and corporate events limits further insights.

Acotec Scientific Holdings Limited Business Overview & Revenue Model

Company Description

Acotec Scientific Holdings Limited (6669) is a company engaged in the development, manufacturing, and sale of medical devices, primarily focusing on interventional medical solutions. The company's core products include drug-coated balloons, stent systems, and other innovative therapeutic devices designed for vascular and non-vascular diseases.

How the Company Makes Money

Acotec Scientific Holdings Limited generates revenue through the sale of its medical devices to hospitals, healthcare institutions, and distributors. The company focuses on producing high-quality interventional medical products, which are used in various medical procedures. Revenue streams are primarily derived from the domestic market in China, with an expanding presence in international markets. Significant partnerships with healthcare providers and ongoing research and development efforts contribute to the company's earnings by continuously enhancing its product offerings and ensuring compliance with regulatory standards.

Acotec Scientific Holdings Limited Financial Statement Overview

Summary

Acotec Scientific Holdings shows strong revenue growth and a healthy balance sheet with low leverage. However, the company faces challenges with profitability margins and cash flow trends, indicating areas for improvement in operational efficiency and cash flow stabilization.

Income Statement

Acotec Scientific Holdings has demonstrated solid revenue growth, with a notable increase from the previous year, indicating a positive growth trajectory. The gross profit margin remains robust, reflecting strong operational efficiency. However, the net profit margin and EBIT margin are relatively constrained, suggesting room for improvement in cost management and operational leverage.

Balance Sheet

The company's balance sheet is healthy, with a strong equity position and a low debt-to-equity ratio, highlighting financial stability and low leverage risk. The equity ratio is high, indicating effective asset management. However, there is limited information on return on equity due to inconsistent net income figures in previous years.

Cash Flow

Acotec Scientific Holdings' cash flow statement indicates challenges, with operating and free cash flows showing negative trends in recent years. However, the company managed to improve its cash position significantly. The lack of available data on free cash flow growth rates limits further analysis.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	523.12M	533.99M	473.85M	395.55M	303.81M	193.97M
Gross Profit	399.51M	402.72M	377.42M	336.35M	265.94M	163.78M
EBITDA	35.01M	112.48M	70.54M	91.17M	-51.02M	-24.66M
Net Income	32.08M	52.28M	14.49M	70.14M	-79.08M	-44.29M
Balance Sheet
Total Assets	1.71B	1.66B	1.61B	1.41B	1.31B	272.94M
Cash, Cash Equivalents and Short-Term Investments	927.21M	809.57M	879.21M	986.46M	1.14B	147.10M
Total Debt	259.67M	202.92M	234.00M	47.78M	24.57M	41.41M
Total Liabilities	371.93M	312.76M	314.53M	134.46M	100.17M	553.95M
Stockholders Equity	1.34B	1.35B	1.30B	1.28B	1.21B	-281.01M
Cash Flow
Free Cash Flow	-54.90M	5.31M	-92.54M	-115.45M	-31.72M	-27.39M
Operating Cash Flow	27.34M	102.79M	-12.88M	-68.75M	-10.48M	-8.77M
Investing Cash Flow	-300.33M	45.02M	-319.22M	-49.17M	-20.48M	-17.73M
Financing Cash Flow	17.53M	-35.24M	-23.21M	-32.87M	1.02B	142.52M

Acotec Scientific Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6669, the sentiment is Positive. The current price of 11.98 is above the 20-day moving average (MA) of 10.90, above the 50-day MA of 9.08, and above the 200-day MA of 7.54, indicating a bullish trend. The MACD of 1.11 indicates Negative momentum. The RSI at 72.75 is Negative, neither overbought nor oversold. The STOCH value of 56.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6669.

Acotec Scientific Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6669	72 Outperform	HK$4.01B	72.19	3.90%	―	10.44%	238.85%
6609	61 Neutral	HK$1.96B	―	-1.28%	―	17.45%	85.71%
Sector *	57 Neutral	HK$14.47B	5.85	-5.77%	4.75%	9.65%	-43.80%
9996	55 Neutral	HK$5.47B	―	-10.43%	―	36.76%	42.89%
2160	52 Neutral	HK$3.06B	―	-2.19%	―	5.32%	89.43%
2500	46 Neutral	HK$1.27B	―	-27.82%	―	-6.12%	0.43%

Acotec Scientific Holdings Limited Corporate Events

Acotec Scientific Holdings Limited Successfully Concludes AGM with All Resolutions Passed

Acotec Scientific Holdings Limited announced that all resolutions proposed at its Annual General Meeting (AGM) held on June 30, 2025, were successfully passed by shareholders through a poll. The resolutions included the adoption of the company’s audited financial statements for 2024, the re-election of certain directors, and the re-appointment of KPMG as auditors. This successful AGM indicates strong shareholder support and stability in the company’s governance, potentially reinforcing its market position and stakeholder confidence.

Acotec Scientific Holdings Limited Establishes Nomination Committee

Acotec Scientific Holdings Limited has outlined the terms of reference for its Nomination Committee, established to identify and recommend suitable candidates for the company’s board of directors. The committee, consisting mainly of independent non-executive directors, will ensure the selection process aligns with applicable laws and regulations, potentially impacting the company’s governance and strategic direction.

Acotec Scientific Gains Approval for New High-Pressure Balloon Catheter

Acotec Scientific Holdings Limited has received approval from the PRC National Medical Products Administration for its Peripheral High-pressure Balloon Dilation Catheter, Armoni-HP®. This product is designed for use in percutaneous transluminal angioplasty in peripheral blood vessels and post-stent dilation, offering a high-strength fiber-composite design to ensure optimal clinical performance. The approval marks a significant step in the company’s product development, potentially enhancing its market position in the PRC healthcare sector.

Acotec Scientific Holdings Announces 2025 Annual General Meeting

Acotec Scientific Holdings Limited, a company incorporated in the Cayman Islands, has announced its annual general meeting scheduled for June 30, 2025, in Beijing. The meeting will address several key resolutions, including the adoption of the company’s audited financial statements for 2024, the re-election of directors, and the re-appointment of KPMG as auditors. Additionally, the board will seek approval to allot and issue additional shares and securities, which could impact the company’s capital structure and shareholder value.

Acotec Scientific Gains Approval for Innovative Catheter in China

Acotec Scientific Holdings Limited announced that it has received approval from the PRC National Medical Products Administration for its Vertebral Artery Paclitaxel-coated Balloon Dilatation Catheter, AcoArt Verbena®. This product is designed for percutaneous transluminal angioplasty in patients with significant vertebral artery stenosis. Clinical trials have shown its efficacy and safety, with a notable reduction in restenosis rates compared to control groups. This approval marks a significant advancement in the treatment of vertebral artery stenosis, potentially reducing the risk of stroke. The company plans to initiate marketing activities in the PRC market, although successful commercialization is not guaranteed.

Acotec Scientific Receives Approval for New Medical Device in China

Acotec Scientific Holdings Limited announced that it has received registration approval from the PRC National Medical Products Administration for its Peripheral Thrombus Separation Stent. This device is designed to enhance the efficiency of vascular interventional procedures by facilitating the removal of obstructive embolic materials, thus reducing procedural complexity and time. The company plans to initiate marketing activities in the PRC market when appropriate, although there is no guarantee of successful market penetration.

Acotec Scientific Gains Approval for New Vascular Device in China

Acotec Scientific Holdings Limited announced that it has received approval from the PRC National Medical Products Administration for its new product, the E-Peridge® Peripheral Scoring Balloon Dilatation Catheter. This device is designed to aid in the pre-dilation of stenotic lesions in peripheral vessels, enhancing vessel preparation for subsequent treatments. The approval marks a significant step in Acotec’s product development and market expansion efforts in China, although the company cautions that successful marketing of the product is not guaranteed.

Acotec Scientific Gains Approval for Innovative Thrombus Treatment Device

Acotec Scientific Holdings Limited announced the approval of its Intelligent Aspiration Sensing Connector by the Beijing Municipal Medical Products Administration. This device, designed to enhance the efficiency of thrombus aspiration procedures through artificial intelligence, is expected to strengthen Acotec’s position in the peripheral thrombus treatment market. The company plans to initiate marketing activities in the PRC market, although successful commercialization is not guaranteed.